NO177526C - Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater - Google Patents

Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater

Info

Publication number
NO177526C
NO177526C NO883306A NO883306A NO177526C NO 177526 C NO177526 C NO 177526C NO 883306 A NO883306 A NO 883306A NO 883306 A NO883306 A NO 883306A NO 177526 C NO177526 C NO 177526C
Authority
NO
Norway
Prior art keywords
pct
pharmaceutically active
preparation
active conjugates
sec
Prior art date
Application number
NO883306A
Other languages
English (en)
Norwegian (no)
Other versions
NO177526B (no
NO883306L (no
NO883306D0 (no
Inventor
Robert Albert Brown
Original Assignee
Laboratoirios Rubio Sa
Central Blood Lab Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoirios Rubio Sa, Central Blood Lab Authority filed Critical Laboratoirios Rubio Sa
Publication of NO883306L publication Critical patent/NO883306L/no
Publication of NO883306D0 publication Critical patent/NO883306D0/no
Publication of NO177526B publication Critical patent/NO177526B/no
Publication of NO177526C publication Critical patent/NO177526C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NO883306A 1986-11-27 1988-07-26 Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater NO177526C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868628398A GB8628398D0 (en) 1986-11-27 1986-11-27 Pharmaceutically-active conjugates
PCT/GB1987/000854 WO1988003810A1 (en) 1986-11-27 1987-11-27 Pharmaceutically active conjugates having improved body tissue binding specificity

Publications (4)

Publication Number Publication Date
NO883306L NO883306L (no) 1988-07-26
NO883306D0 NO883306D0 (no) 1988-07-26
NO177526B NO177526B (no) 1995-06-26
NO177526C true NO177526C (no) 1995-10-04

Family

ID=10608055

Family Applications (1)

Application Number Title Priority Date Filing Date
NO883306A NO177526C (no) 1986-11-27 1988-07-26 Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater

Country Status (10)

Country Link
US (1) US5151412A (de)
EP (1) EP0333740B1 (de)
JP (1) JP2721830B2 (de)
AT (1) ATE68977T1 (de)
AU (1) AU610104B2 (de)
DE (1) DE3774279D1 (de)
DK (1) DK168693B1 (de)
GB (1) GB8628398D0 (de)
NO (1) NO177526C (de)
WO (1) WO1988003810A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340573A3 (de) * 1988-04-30 1990-05-30 BASF Aktiengesellschaft Neue Proteine, ihre Herstellung und Verwendung
US4892826A (en) * 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
FI912858A0 (fi) * 1988-12-20 1991-06-13 Jolla Cancer Res Found Polypeptidpolymerkonjugat aktiva vid botande av saor.
EP0429663A1 (de) * 1989-06-13 1991-06-05 Nippon Soda Co., Ltd. Der menschlichen prourokinase ähnliche polypeptide und verfahren zu deren herstellung
US5013726A (en) * 1989-09-12 1991-05-07 Ivy Jeffery W External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion
US5124320A (en) * 1989-09-12 1992-06-23 Ivy Jeffery W An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion
GB9023149D0 (en) * 1990-10-24 1990-12-05 British Bio Technology Proteins and nucleic acids
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
DK0598719T3 (da) * 1991-07-31 1999-06-14 Antex Biolog Inc Receptorkonjugater til destinering af lægemidler og andre midler
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US5821074A (en) * 1993-12-21 1998-10-13 Abbott Laboratories Method and compositions for enhancing aminolevulinic acid dehydratase assay
CA2253204A1 (en) * 1996-05-03 1997-11-13 Roger S. Cubicciotti Prodrug compositions and drug delivery methods using synthetic receptors
CA2315702A1 (en) * 1997-12-24 1999-07-08 Immunex Corporation V196 dna and polypeptides
DE69932247T2 (de) * 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
IN190822B (de) * 1998-12-24 2003-08-23 Council Scient Ind Res
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7678767B2 (en) * 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
EP2064300A4 (de) * 2006-09-20 2013-05-22 Pneumrx Inc Gewebehaftzusammensetzungen und verfahren dafür

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
AR241654A1 (es) * 1982-05-05 1992-10-30 Genentech Inc Procedimiento para producir activador de plasminogeno de tejido humano.
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
JPS59134732A (ja) * 1983-01-21 1984-08-02 Green Cross Corp:The フイブロネクチン・生理活性物質複合体の製造法
JPS60226819A (ja) * 1984-04-25 1985-11-12 Green Cross Corp:The フイブロネクチン複合体
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
US4587122A (en) * 1985-04-23 1986-05-06 The Green Cross Corporation Fibronectin-dextran-drug complex and method of preparation thereof

Also Published As

Publication number Publication date
EP0333740B1 (de) 1991-10-30
DK168693B1 (da) 1994-05-24
DE3774279D1 (de) 1991-12-05
NO177526B (no) 1995-06-26
DK420988A (da) 1988-07-27
AU8277387A (en) 1988-06-16
DK420988D0 (da) 1988-07-27
NO883306L (no) 1988-07-26
JP2721830B2 (ja) 1998-03-04
ATE68977T1 (de) 1991-11-15
JPH02501305A (ja) 1990-05-10
AU610104B2 (en) 1991-05-16
NO883306D0 (no) 1988-07-26
US5151412A (en) 1992-09-29
EP0333740A1 (de) 1989-09-27
GB8628398D0 (en) 1986-12-31
WO1988003810A1 (en) 1988-06-02

Similar Documents

Publication Publication Date Title
NO883306L (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
BR9107074A (pt) Imunorreagente radioativo de marcacao,composicao e processo de formacao de imagem diagnostica,composicao terapeutica,processo de tratamentod e silios doentios e composicao da materia
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
HUT56133A (en) Process for treating viral infections with functional derivatives of icam-1 intercellular adhesion molecule
PL335140A1 (en) Therapeutic agent for treating lymphatic system carcinomas
MXPA03009408A (es) Factor de crecimiento endotelial vascular 2.
NO903449D0 (no) Fremgangsmaate for aa behandle underjordiske formasjoner.
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE3781652D1 (de) Zubereitung, geeignet fuer die behandlung von darmstoerungen.
EP0869801A4 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE114974T1 (de) Abgabe von cytotoxischen mitteln.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
BR8806062A (pt) Processo para a preparacao de uma composicao concentrada estavel,bombeavel e despejavel,processo para a preparacao de uma composicao amaciante de tecidos,composicao concentrada,e composicao para tratamento de texteis
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
HUT36783A (en) Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane
DE69929683D1 (de) Antisense modulierung von lfa-3
PT1141019E (pt) Fragmento da glicoproteina cd55/daf para a obtencao de medicamentos antitumorais com elevada eficacia assim como processo para a sua utilizacao